United Kingdom Archives

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 9 Aug 2015

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

Prokarium Ltd today announced a new £377k (€534k) funding from SynbiCITE to develop an innovative Chlamydia vaccine using synthetic biology. The new therapy could help the 92 million people affected by Chlamydia each year and help fighting one of the most common sexually transmitted infections. The £498k (€706k) Chlamydia vaccine project is funded at £377k (€534k) from SynbiCITE, the UK’s Innovation and […]

August 9, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

AstraZeneca Adds New Antisense Drugs to its Pipeline

Isis Pharmaceuticals and AstraZeneca extend their collaboration to discover and develop antisense therapies. After cancer, the partners are now targeting cardiovascular, metabolic and renal diseases. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 4 Aug 2015

A 100% Successful Ebola Vaccine Available in a Record Time

It’s a really good news in the fight against Ebola. A vaccine has shown 100% success to prevent the disease during the outbreak in Guinea! The vaccine, which has been tested in a record time, can be the key to end the west African epidemics. In an interim analysis published by The Lancet, the new vaccine has […]

August 4, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 31 Jul 2015

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance the companies entered into in February 2013. Heptares will use MorphoSys’s antibody library to generate a new candidate targeting a GPCR, one of the largest class of pharmaceutical target currently on the market. In February 2013, MorphoSys and Heptares […]

July 31, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 29 Jul 2015

How to create a late-stage Biotech company in record time? Ask Novartis!

Mereo BioPharma. This name doesn’t ring a bell? From now on, you should keep it in mind as it could rapidly become a rising star on the European Biotech scene. Launched five months ago, the company has already three candidates in phase II and just raised $119m (approximately €108m) from private investors! Mereo has everything […]

July 29, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 28 Jul 2015

Struggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M

The Pharma giant AstraZeneca is still struggling even if in better shape. It just sold one of his rare disease drug already on the market to THE rare disease Biotech Genzyme, now part of Sanofi. AstraZeneca is under pressure. Last April 2015, the company reported a fall in revenues and profits (7% lower than previous […]

July 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 24 Jul 2015

MGB puts a new spin on fighting multi-resistant bacteria

MGB Biopharma wants to tackle multi-resistant bacteria with their newly developed anti-infectives. Its lead candidate, MGB-BP-3 is now entering Phase I. Biotech companies use several approaches when it comes to killing bacteria, especially when these are resistant against antibiotics. In our last news, we have seen, Ferring betting on bacteriophages or ELIGO using CRISPR on this purpose. The Scottish […]

July 24, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

Man can See Again thanks to his Bionic Eye

Major Breakthrough in eye research! The world’s first ever dry Age Related Macular Degeneration patient received Second Sight Medical Products’ ‘bionic eye’. Initial tests on the 80-year-old individual with no central vision showed that the treatment allowed him to see the outline of people again. 80-year-old Ray Flynn, from Audenshaw in Manchester, is one of the 20 […]

July 23, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Nanopore cashes in €100M to revolutionize Next-gen sequencing

Personalized medicine is now becoming a reality thanks to next-gen sequencing. Illumina still remains Number 1 in the field, but Oxford Nanopore is on its way up to the top of the charts. The UK-based company raised €100M to become a serious challenger with its cheap and small technology. Oxford Nanopore Technologies, a spin out […]

July 22, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been published in Nature Medicine. This is the first report on TCR engineered T-cell therapy that shows durable persistence in patients! After its successful intoduction on […]

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Jul 2015

Genetically Modified Insects: Designed to Cause Extinction

Insects can be very dangerous creatures, spreading diseases and destroying the yield. The British biotech company Oxitec developed a unique approach to potentially wipe out some harmful populations of these tiny animals. Studies on the diamondback moth are already showing good results! Farmers around the world struggle with a serious pest caused by the diamondback moth […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

AstraZeneca Adds New Antisense Drugs to its Pipeline

A 100% Successful Ebola Vaccine Available in a Record Time

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

How to create a late-stage Biotech company in record time? Ask Novartis!

Struggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M

MGB puts a new spin on fighting multi-resistant bacteria

Man can See Again thanks to his Bionic Eye

Nanopore cashes in €100M to revolutionize Next-gen sequencing

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Genetically Modified Insects: Designed to Cause Extinction

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!